louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03966625: Serological Identification of Celiac Disease in Kids
Official title: Serological Identification of Celiac Disease in Kids (Swedish: Screening för Celiaki på Barnmottagning)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Celiac Disease in Children
Pediatric Disorder
Health, Subjective
Growth Delay
Keywords: screening
Lead sponsor: Sahlgrenska University Hospital
Sponsor class: OTHER
Collaborators: name: Vastra Gotaland Region
First posted: 2019-05-29
Enrollment: 496
Sex: ALL
Minimum age (years): 2
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients at pediatric outpatient clinics in Gothenburg metro area

Brief summary: The investigators aim to examine the feasibility of incorporating serological celiac disease (CD) screening into general pediatric outpatient clinics in Sweden and through structured monitoring examine the effects of diagnosing and treating screening-detected CD.

Screening will be tailored to general pediatric outpatient clinics in the Gothenburg metropolitan area with the goal to screen 1000 children over four months. Screening for CD will be carried out by measuring tissue transglutaminase autoantibodies (TGA) in blood. Children who are persistently TGA positive will be enrolled into a 6-12-month follow-up protocol responsible for diagnosing CD, installation of gluten-free diet and to assess their short-term impact upon the child's wellbeing. Other components to assess include (I) the feasibility to incorporate CD screening into busy pediatric practices; (II) parental/child interest in, and satisfaction with, participating in a CD screening program and (III) identifying key considerations for a possible scaled-up, broad-based, CD screening.


Eligibility criteria: Inclusion Criteria:

* Aged 2-17 years old
* Patient at pediatric outpatient clinics in Gothenburg metro area
* Parental and adolescent consent to screening

Exclusion Criteria for serological screening:

* Established celiac disease diagnosis
* Type 1 diabetes

Primary outcomes:
measure: Number of participants diagnosed with celiac disease
timeFrame: Assessed after 6-12 months of follow-up
Secondary outcomes:
measure: Number of participants identified with celiac disease autoimmunity
timeFrame: Assessed after performed two tests of TTG (apprx. 1-2 months after enrollment)
Other outcomes:
Locations:
city: Gothenburg
country: Sweden
facility: Queen Slivia Children's Hosptial
city: Gothenburg
country: Sweden
facility: BUMM Hisingen
Study officials:
References:
Clinical trial NCT06513325: Association of Perceived Occupational Performance and Satisfaction, Balance, Gait, and Fear of Falling in Older Adult With Mild Cognitive Impairment
Official title: Association of Perceived Occupational Performance and Satisfaction, Balance, Gait, and Fear of Falling in Older Adult With Mild Cognitive Impairment
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Mild Cognitive Impairment
Gait
Balance
Occupational Problems
Lead sponsor: Gulhane School of Medicine
Sponsor class: OTHER
First posted: 2024-07-22
Enrollment: 36
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study included people over 65 with mild cognitive impairment

Brief summary: This study was designed to investigate the occupational performance and balance, gait, and fear of falling in older adults with MCI. Balance and gait of the older adults were assessed with the Tinetti balance and gait test, fear of falling with the Tampa Scale for Kinesiophobia and occupational performance with the Canadian Occupational Performance Measure (COPM). The relationship between COPM and other parameters was analysed by Spearmen's test.


Eligibility criteria: Inclusion Criteria:

* people over 65 with mild cognitive impairment who could understand and follow instructions

Exclusion Criteria:

* Individuals who were unable to participate in the study due to a chronic condition or the use of assistive devices such as wheelchairs or crutches

Primary outcomes:
measure: Canadian Occupational Performance Measure
timeFrame: 10 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: University of Health Sciences
Study officials:
affiliation: Saglik Bilimleri Universitesi
name: Güllü AYDIN YAĞCIOĞLU, Asst. prof
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03174925: Ultrasound Elastography in Imaging Patients With Thyroid Nodules
Official title: Elastography in Thyroid Nodule Evaluation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Malignant Thyroid Gland Neoplasm
Thyroid Gland Nodule
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2017-06-05
Enrollment: 55
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Siemens Acuson S3000 ultrasound system
Primary purpose: DIAGNOSTIC

Brief summary: This clinical trial studies how well ultrasound elastography works in assessing the cancer status of potentially malignant thyroid nodules.

Detailed description: PRIMARY OBJECTIVES:

Determine the utility of ultrasound elastography in evaluation of thyroid nodules being evaluated for the presence of cancer.

Elastography measures the passages of ultrasound shear waves through tissue to gauge the stiffness and compressibility of the tissue, collectively "tissue stiffness," and may be a better way to image thyroid nodules. Tissue stiffness is a physiological parameter that is being evaluated for differences between non-cancerous (benign) and cancerous thyroid nodules.

Participants will undergo elastography over the 10 minutes prior to either fine needle aspiration of a biopsy specimen or surgical resection of the thyroid nodule. Tissue specimens from the biopsy specimen or surgical resection will be assessed pathologically to determine actual cancer status.

Eligibility criteria: Inclusion Criteria:

* Presence of a thyroid nodule that is amenable to ultrasound guided fine needle aspiration

Exclusion Criteria:

* Patients who are unable to lie supine for a biopsy
* Pregnant patients

Primary outcomes:
measure: Stiffness of Thyroid Nodules as Measured by Elastography
timeFrame: 1 week
Secondary outcomes:
Other outcomes:
Locations:
city: Palo Alto
country: United States
facility: Stanford University, School of Medicine
state: California
Study officials:
affiliation: Stanford Cancer Institute
name: Aya Kamaya
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06270225: A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.
Official title: A Randomized, Open-label, Active-Controlled Phase II Trial to Evaluate the Efficacy and Safety of SSGJ-613 for Prophylaxis Against Acute Gouty Arthritis Flares in Subjects Initiating Urate-Lowering Treatment.
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Gout Arthritis
Lead sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2024-02-21
Enrollment: 157
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the efficacy and safety of recombinant anti-interleukin-1β humanized monoclonal antibody injection in Chinese gout participants Initiating Urate-Lowering Treatment.


Eligibility criteria: Inclusion Criteria:

* Must be 18 Years to 75 Years, both male and female.
* BMI ≤40 kg/m2.
* Meeting the American College of Rheumatology (ACR) 2015 criteria for the classification of gouty arthritis.
* ≥2 acute gout flares within 1 year prior to screening.
* Willingness to initiate urate-lowering treatment or to initiate urate-lowering treatment within 7 days prior to administration.

Exclusion Criteria:

* Gout caused by radiotherapy/chemotherapy, organ transplantation, tumors, etc.
* Evidence/suspicion of infectious/septic arthritis, or other acute inflammatory arthritis.
* Presence of severe renal function impairment.
* Intolerance of subcutaneous injection.
* Known presence or suspicion of active or recurrent bacterial, fungal, or viral infection at the time of enrollment.
* Live vaccinations within 8 weeks prior to the start of the study.
* Use of forbidden therapy

Primary outcomes:
measure: Numbers of acute gout flares
timeFrame: 12 weeks
Secondary outcomes:
measure: Numbers of acute gout flares
timeFrame: 24 weeks
measure: Proportions of subjects with at least 1 acute gout flare
timeFrame: 12 weeks
measure: Proportions of subjects with at least 1 acute gout flare
timeFrame: 24 weeks
measure: Time from randomization to first acute flare.
timeFrame: 24 weeks
measure: Duration of acute gout flares.
timeFrame: 12 weeks
measure: Duration of acute gout flares.
timeFrame: 24 weeks
measure: Subject's overall assessment of response to treatment
timeFrame: 24 weeks
measure: Investigator's overall assessment of response to treatment
timeFrame: 24 weeks
measure: 36-item Short Form Survey (SF-36)
timeFrame: 24 weeks
measure: Adverse events (AE)
timeFrame: 24 weeks
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Huashan Hospital Fudan University-Rheumatology
state: Shanghai
Study officials:
affiliation: Shanghai Huashan Hospital Fudan University-Rheumatology
name: Hejian Zou, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
name: Qinghong Zhou
role: STUDY_DIRECTOR
References:
Clinical trial NCT02469025: Effects of Grade III Traction-mobilization in End-range Joint Position in Patients With Hip Osteoarthritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Osteoarthritis, Hip
Lead sponsor: Universidad de Zaragoza
Sponsor class: OTHER
First posted: 2015-06-11
Enrollment: 50
Sex: ALL
Minimum age (years): 45
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Lower limb osteoarthritis is a major health problem in the westernized countries. The current gold standard treatment is joint replacement. However clinical guidelines recommend physical therapy as first option for these patients. Manual therapy has reported good reports in function, range of motion and pain in patients with hip osteoarthritis. The main aim of this study is to test the effects of a manual therapy protocol based on manual traction mobilization of the hip joint in an end range position and compare them with the effects achieve with the same protocol based on manual traction mobilization of the hip joint in a resting position. The investigators will use the caudal traction mobilization described by Kaltenborn. The study will test the effects of both treatments in passive range of motion, function and pain after three weeks of treatment, three weeks after finalizing the treatment and six weeks after.


Eligibility criteria: Inclusion Criteria:

* Hip osteoarthritis diagnosis
* Diminished range of motion
* Sign the informed consent

Exclusion Criteria:

* Contraindications to Manual Therapy.
* Sensitivity impairments in low back, pelvis, knee or foot regions.
* Being involved in other physical therapy treatments
* To change medication use during the study

Primary outcomes:
measure: Change from Baseline in Passive Hip Range of Motion after intervention, at 3 weeks post-intervention and at 6 weeks post intervention
timeFrame: 3 weeks, 6 weeks, 9 weeks
Secondary outcomes:
measure: Changes from Baseline in Functional Tests (TUG, fast-paced walk test, stair climb test, 30sec. chair stand test), after intervention, at 3 weeks post-intervention and at 6 weeks post intervention
timeFrame: 3 weeks, 6 weeks, 9 weeks
measure: Change from Baseline in Pain on the Visual Analog Scale after intervention, at 3 weeks post-intervention and at 6 weeks post intervention
timeFrame: 3 weeks, 6 weeks, 9 weeks
measure: Change from Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale after intervention and at 6 weeks post intervention
timeFrame: 3 weeks, 9 weeks
Other outcomes:
Locations:
city: Zaragoza
country: Spain
facility: Unidad de Investigación en Fisioterapia. Universidad de Zaragoza
Study officials:
References:
Clinical trial NCT02784925: Evaluate Patients With Chronic Hepatitis by Three-dimensional Force-controlled Ultrasound Measurement
Official title: Evaluate Patients With Chronic Hepatitis Before and After Treatment of Body Index by Three-dimensional Force-controlled Ultrasound Measurement of Subcutaneous Fat
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Fatty Liver
Lead sponsor: Taipei Medical University WanFang Hospital
Sponsor class: OTHER
Collaborators: name: Taipei Medical University
First posted: 2016-05-27
Enrollment: 30
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Ultrasound (US) B mode image is an alternative method to measure tissue structure and has proven to be an accurate technique to measure subcutaneous fat thickness. However, pressing the transducer onto the skin with too much force will significantly reduce the subcutaneous adipose tissue thickness. In this study, a force controlled system combined with US transducer was used for 3D subcutaneous fat imaging and reconstruction.

Detailed description: The diagnosis of fatty liver (steatosis) is made when fat in the liver exceeds 5-10% by weight. Fatty liver (FL) is commonly associated with alcohol or metabolic syndrome (diabetes, hypertension, obesity, and dyslipidemia), but can also be due to any one of many causes. Most people were detected from serum lipid abnormalities in the physical examination, and confirmed as the fatty liver disease by ultrasound imaging. In some previous studies, ultrasound was reported to provide an accurate and reliable measurement tool for the thickness measurements of subcutaneous adipose tissue. This method can overcome some limitations of the skinfold thickness measurements. Ultrasound (US) B mode image is an alternative method to measure tissue structure and has proven to be an accurate technique to measure subcutaneous fat thickness. However, pressing the transducer onto the skin with too much force will significantly reduce the subcutaneous adipose tissue thickness. In this study, a force controlled system combined with US transducer was used for 3D subcutaneous fat imaging and reconstruction. Finally, the correlations between body fat percentage and subcutaneous fat in steatosis patients have been investigated. The body fat percentage was determined by dual energy X-ray absorptiometry (DEXA, GE Lunar iDXA canner) and bioelectrical impedance analysis (BIA, Omron，HBF-370), and then, the correlation between body fat percentage and subcutaneous adipose tissue in normal and steatosis patients have been evaluated.

Eligibility criteria: Inclusion Criteria:

* Aged between 20-65 adults who are confirmed have fatty liver by echo

Exclusion Criteria:

* none

Primary outcomes:
measure: Subcutaneous Fat in Steatosis Patients
timeFrame: up to 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03215225: Endodontic Root-canal Treatments Evaluated After Long-term Time
Official title: Long-term Evaluation of Endodontic Root Canal Treatments: Complication, Factors Affecting Failure, New Disease and Success
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Root Canal Treatment
Endodontic Disease
Keywords: Endodontology
Endodontics
Lead sponsor: University of Bologna
Sponsor class: OTHER
First posted: 2017-07-12
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Similar geographic provenience

Brief summary: The aim of the study was to evaluate the root canal treatments performed from 1989 to 1995. Type of complication, success, new endodontic diseases and number of success were reported. Mean clinical parameters were clinical symptoms and presence/absence of apical radiolucency.

Detailed description: See previous papers (Pirani et al., Odontology, 2015)

Eligibility criteria: Inclusion Criteria:

Patients affected by endodontic disease and able to attend a recall hygien program

Exclusion Criteria:

* Sistemic disease Cancer Inability to attend a recall hygien program

Primary outcomes:
measure: Health Patients
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01072825: A European Network for the Investigation of Gender Incongruence
Official title: A European Network for the Investigation of Gender Incongruence
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Physical and Psychological Evaluation of Hormonal Therapy in Transsexual Persons
Lead sponsor: University Hospital, Ghent
Sponsor class: OTHER
First posted: 2010-02-22
Enrollment: 125
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: transsexual persons older than 18 years, who are not yet treated with hormonal therapy

Brief summary: The physical and psychological effects of the hormonal treatment of transsexual persons are not sufficiently described. 'Transparency' wants to answer this question in a prospective manner, in a multicenter study to describe these effects. The low prevalence of transsexualism was the stimulus to search for European partners for this Protocol. A common standardized hormonal protocol was designed.


Eligibility criteria: Inclusion Criteria:

* Transsexual persons older then 18 years, who are not yet treated with hormonal therapy.

Exclusion Criteria:

-

Primary outcomes:
measure: physical and psychological effects of the hormonal treatment of transsexual persons
timeFrame: annually
Secondary outcomes:
Other outcomes:
Locations:
city: Gent
country: Belgium
facility: Genderteam UZ Gent
city: Florence
country: Italy
city: Amsterdam
country: Netherlands
facility: VU University Medical CenterAmsterdam
city: Oslo
country: Norway
facility: Rikshospitalet University Hospital, University of Oslo
Study officials:
affiliation: University Hospital, Ghent
name: Guy T'Sjoen, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Shadid S, Abosi-Appeadu K, De Maertelaere AS, Defreyne J, Veldeman L, Holst JJ, Lapauw B, Vilsboll T, T'Sjoen G. Effects of Gender-Affirming Hormone Therapy on Insulin Sensitivity and Incretin Responses in Transgender People. Diabetes Care. 2020 Feb;43(2):411-417. doi: 10.2337/dc19-1061. Epub 2019 Nov 18.
citation: Auer MK, Ebert T, Pietzner M, Defreyne J, Fuss J, Stalla GK, T'Sjoen G. Effects of Sex Hormone Treatment on the Metabolic Syndrome in Transgender Individuals: Focus on Metabolic Cytokines. J Clin Endocrinol Metab. 2018 Feb 1;103(2):790-802. doi: 10.1210/jc.2017-01559.
citation: Bultynck C, Pas C, Defreyne J, Cosyns M, den Heijer M, T'Sjoen G. Self-perception of voice in transgender persons during cross-sex hormone therapy. Laryngoscope. 2017 Dec;127(12):2796-2804. doi: 10.1002/lary.26716. Epub 2017 Jul 21.
Clinical trial NCT02528825: Effect-site Concentration of Remifentanil for Smooth Removal of the Double-lumen Endotracheal Tube
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Remifentanil Concentration for Smooth Emergence
Lead sponsor: Ajou University School of Medicine
Sponsor class: OTHER
First posted: 2015-08-19
Enrollment: 25
Sex: ALL
Minimum age (years): 19
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: Smooth emergence is important for patient safety and satisfaction. Coughing during emergence is associated with detrimental effects like laryngospasm, sore throat, hoarseness, negative pressure pulmonary edema and bleeding at surgical site 1. Especially sore throat and hoarseness are most common complications after extubation 2,3 and closely related to patient satisfaction 4. Using double lumen tube (DLT) increase the incidence of hoarseness and airway injury than using single lumen tube for it has large size5,6. Various technique and drugs have been proposed for reducing coughing during extubation including smooth emergence 1,7-11 and this is closely correlate with reducing sore throat and hoarseness 12. One of the proposed technique, the use of short acting opioids are prefered13-15 because it can be maintained during emergence with less respiratory depression. Remifentanil is a potent short acting opioid and several studies choose remifentanil combined with other anesthetic agents 1,15,16. There is a study about the EC50 and EC95 of remifentanil in effect site Target controlled infusion(TCI) for preventing cough during emergence after thyroidectomy with propofol-remifentanil anesthesia 15 but no study about the proper dose of remifentanil for smooth DLT extubation.

The purpose of this study was to evaluate the EC50 and EC95 of remifentanil in effect-site TCI for preventing cough during extubation of DLT in total TIVA with propofol and remifentanil.


Eligibility criteria: Inclusion Criteria:

* ASA I-II,
* Undergoing general anesthesia with DLT for lung wedge resection

Exclusion Criteria:

* Anticipated difficult airway
* Surgical duration of \> 120 min,
* Patient with gastroesophageal reflux or asthma, chronic obstructive disease and upper respiratory infection were excluded from the study.

Primary outcomes:
measure: Smooth emergence success or fail
timeFrame: from the time of remifentanil equivalent state( postop 5 minute) to extubation
Secondary outcomes:
Other outcomes:
Locations:
city: Suweon
country: Korea, Republic of
facility: Jiyoung Yoo
state: Kyunggido
Study officials:
affiliation: Ajou University School of Medicine
name: Ji Young Yoo, md
role: PRINCIPAL_INVESTIGATOR
References: